Absci (NASDAQ:ABSI – Get Free Report) will likely be releasing its earnings data after the market closes on Tuesday, March 18th. Analysts expect Absci to post earnings of ($0.23) per share and revenue of $1.77 million for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.
Absci Stock Performance
NASDAQ:ABSI opened at $3.14 on Monday. The company has a quick ratio of 5.63, a current ratio of 5.63 and a debt-to-equity ratio of 0.01. The company has a market cap of $360.65 million, a P/E ratio of -3.38 and a beta of 2.09. Absci has a fifty-two week low of $2.45 and a fifty-two week high of $6.72. The firm’s 50 day moving average is $3.87 and its two-hundred day moving average is $3.70.
Wall Street Analyst Weigh In
A number of research firms have weighed in on ABSI. KeyCorp cut their price target on shares of Absci from $6.00 to $5.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. Needham & Company LLC began coverage on shares of Absci in a research note on Wednesday, January 22nd. They set a “buy” rating and a $9.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target on shares of Absci in a research note on Friday, January 17th. Finally, Guggenheim reaffirmed a “buy” rating and set a $10.00 price target on shares of Absci in a research note on Tuesday, December 3rd. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $8.57.
About Absci
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.
Featured Stories
- Five stocks we like better than Absci
- Why Are These Companies Considered Blue Chips?
- How to Build the Ultimate Everything ETF Portfolio
- What is a buyback in stocks? A comprehensive guide for investors
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Absci Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Absci and related companies with MarketBeat.com's FREE daily email newsletter.
